Myeloid derived suppressor cells (MDSCs) from tumor-bearing mice are important negative regulators of anti-cancer immune responses, but the role for immature myeloid cells (IMCs) in non-tumor-bearing mice in the regulation of immune responses are poorly described. We studied the immune-suppressive activity of IMCs from the bone marrow (BM) of C57Bl/6 mice and the mechanism(s) by which they inhibit T-cell activation and proliferation. IMCs, isolated from BM by high-speed FACS, inhibited mitogen-induced proliferation of CD4 + and CD8 + T-cells in vitro. Cell-to-cell contact of T-cells with viable IMCs was required for suppression. Neither neutralizing antibodies to TGFb1, nor genetic disruption of indolamine 2,3-dioxygenase, abrogated IMC-mediated suppressive activity. In contrast, suppression of T-cell proliferation was absent in cultures containing IMCs from interferon-c (IFN-c) receptor KO mice or T-cells from IFN-c KO mice (on the C57Bl/6 background). The addition of NO inhibitors to co-cultures of T-cells and IMC significantly reduced the suppressive activity of IMCs. IFN-c signaling between T-cells and IMCs induced paracrine Nitric Oxide (NO) release in culture, and the degree of inhibition of T-cell proliferation was proportional to NO levels. The suppressive activity of IMCs from the bone marrow of tumor-free mice was comparable with MDSCs from BALB/c bearing mice 4T1 mammary tumors. These results indicate that IMCs have a role in regulating T-cell activation and proliferation in the BM microenvironment.
Introduction
Normal BM contains a heterogeneous population of cells, including immature macrophages, granulocytes, and myeloid dendritic cells. Immature myeloid cells, termed myeloid-derived suppressor cells (MDSC), are expanded in tumor-bearing mice, and in patients with cancer, trauma, and autoimmunity [1, 2] . The phenotype of MDSCs described in different tumor models is based upon their expression of one or more myeloid markers including the b2 integrin CD11b [3] , MCSF-R [4] , CD124 [5] , and the two epitopes of the myeloid marker GR-1, Ly6C [6] and Ly6G [7] . While an immunosuppressive role of tumor-associated MDSCs has been well characterized in murine models [8] , the immunomodulatory functions of BM-derived CD11b + GR-1 + IMCs from normal mice has not been well studied. Ly6G + Ly6C low granulocytic and Ly6G + Ly6C hi monocytic MDSCs, both of which inhibit T-cell activation and proliferation in tumor-bearing mice via NO-dependent and NO-independent mechanisms [9, 10] . Although a number of reports have described natural suppressor (NS) myeloid cells in BM from non-tumor bearing animals [11, 12] , most studies during the last 20 years have focused on tumor-associated myeloid-derived suppressor cells and suggest that BM-derived CD11b + GR-1 + immature myeloid cells (IMCs) in normal, tumor-free mice lack immunosuppressive activity [8, 13] .
Thus, the role of IMCs in the immune homeostasis of non-tumor bearing animals remains only partially understood. The BM is a common site for tumor metastasis for a variety of cancers, suggesting that the BM environment maybe immuno-suppressive and limit adaptive immune responses to metastatic cancer. The current study was undertaken to characterize the immunosuppressive activity of myeloid precursors from the BM of nontumor-bearing mice. To do this, we isolated different populations of immature myeloid cells and studied their immune suppressive effect on T ell proliferation in vitro. We report herein that CD11b 
Materials and Methods

Mice and cell lines
BALB/c mice, C57Bl/6, BA (CD90.1 congenic strain of B6), and genetic knockout strains (KO) on the C57Bl/6 background (IDO KO, IFN-c KO, IFN-c receptor KO and IL-12 KO) were purchased from the Jackson Laboratory (Bar Harbor, ME). Mice were housed under specific-pathogen free conditions and used between 2 and 6 months of age. Animal experiments were carried out under an Institutional Animal Care and Use Committee (IACUC). The protocol was approved by the committee on the Ethics of animal Experiments of the university of Emory (Permit number: A3180-01). LBRM 33-5A4, a B10-derived T-cell lymphoblastic lymphoma cell line [14] and the 4T1 breast cancer cell line, derived from BALB/c were purchased from ATCC. Cells were cultured in RPMI supplemented with 10% fetal bovine serum, 0.4 mmol/L sodium pyruvate and antibiotics (penicillin, streptomycin). 4T1 cells (1610 6 in 100 mL PBS) were injected subcutaneously into the right flank of female BALB/c mice.
Preparation of bone marrow cells and splenocytes
Bone marrow cells (BMC) were harvested from the femur bones of mice, cutting off each end, and flushing out the bone marrow with PBS. Splenocytes and BMC were passed through a 70 mm nylon mesh cell strainer [15] , pelleted, re-suspended in red blood cell lysis buffer, followed by washing in PBS. T-cells were purified by negative selection after incubating splenocytes with biotinylated anti-CD11b, B220 (B cells), DX5 (NK cells), and Ter119 (RBCs) antibodies using an LS immunomagnetic column system (MACS, Miltenyi Biotech) according to the manufacturer's instructions. Tcell purity was 85-90% as determined by FACS.
Antibodies and Reagents
Monoclonal antibody (Mab) details are provided in Table 1 . Neutralizing antibodies against TGF-b1 (clone 2AR2, 1.5-5 mg/ ml), and IL-4 (clone 11B11, 50 mg/ml) IL10 (clone JES5-16E3, 5 mg/ml), were purchased from eBioscience (Table 1) . INOS inhibitors L-NG-monomethyl arginine (L-NMMA, Sigma-Aldrich, St. Louis), L-NIL, (N6-(1-iminoethyl)-lysine, hydrochloride, Biotium, Inc, USA) and L-NIO (N5-(1-iminoethyl)-L-ornithine, dihydrochloride, Biotium) were added to T-cell-IMC cultures.
Cell sorting
BM cells were washed with 16 PBS, FC blocked with anti-CD16/CD32 Mab (Fc Block, BD Bioscience) prior to incubation with 2 mg/ml anti-CD11b (APC-Cy7) and anti-GR-1 (FITC) Mabs in combination with a pool of PE-conjugated lineage Mabs against Ter-119, CD3, CD45R and DX-5 in 16 PBS with 1% BSA for 20 min at 4uC. After washing with 16 PBS, cells were resuspended in RPMI-1640 supplemented with 10% FBS and 1% penicillin/streptomycin, and sorted using a FACS Aria cell sorter and FACSDiva software version 5. 
Morphological Analysis
Cytospin slide preparations of sorted purified cells were made using a Shandon Southern Cytospin (Thermo Scientific, Walthman, MA). Giemsa staining (1/20 dilution) was done for 30 minutes and cells were photographed at 636 using a Zeiss axioplan 2 upright microscope (Carl Zeiss, Inc).
Carboxyfluorescein diacetate succinimidyl diester (CFSE) labeling and Proliferation Assay
Staining conditions were optimized to distinguish proliferated cells from undivided cells. CFSE (Invitrogen Corporation, Carlsbad, CA) was diluted in DMSO at a stock concentration of 5 mM, which was then diluted to the final working concentration of 1 mM. Whole splenocytes or T-cells (1610 6 cells/ml) were stained using 1 mM CFSE in PBS for 10-min at 37uC. Staining was quenched by the addition of two volumes of ice-cold RPMI-1640 (10% FBS, 1% penicillin/streptomycin) and incubation on ice for 5 min in RPMI and 10% FBS. Stained cells were washed twice and resuspended to the desired concentration. Freshly CFSE labeled T-cells were co-cultured at a density of 1610 6 /per well with or without fresh CD11b
+ cells (ratio 1/1) in the presence of anti-CD3/CD28 Dynabeads, or with CON A (250 ng/ml). In some experiments, sorted IMCs were fixed in 1% Para formaldehyde (PFA), pH 7.0 for 1 hour at 4uC and washed several times prior to co-culture with T-cells. Cell-cell contact dependency was evaluated using a 0.4 mm pore size Transwell plate (Corning Costar, Cambridge, MA). After 5 days, cultured T-cells were harvested, stained with fluorochromeconjugated anti-CD3, anti-CD4 and anti-CD8 antibodies, followed by the addition of 7-amino-actinomycinD (7-AAD), then analyzed by flow cytometry to determine the CFSE profiles of viable (7-AAD negative) T-cell populations, acquiring at least 150,000. The proliferation index (PI) of CD4 or CD8 T-cells was determined by analyzing the CFSE histograms [16] . Inhibition of proliferation was calculated as follows: [1002(PI sample/PI control)*100 = % suppression]. The percentages of apoptotic and dead cells were quantified using Annexin V and 7-AAD (BD Pharmingen). Extracellular Nitric oxide measurement
Culture supernatants were mixed with Griess reagent (Molecular Probes, Eugene, OR) based on the manufacturer's instructions and absorbance was measured at 570 nm using a microplate plate reader (Epoch-BioTek). Nitrite concentrations were determined by comparing the sample absorbance values versus a standard curve generated by serial dilution of 50 mM sodium nitrite.
Intra cellular assay of Nitric oxide
To measure intracellular NO, DAF-FM (4-amino-5-methylamino-2,7-difluorescein) (Molecular Probes, OR, USA) was used. DAF-FM readily diffuses into cells and within the cytoplasm releases DAF-FM by the action of intracellular esterase. DAF-FM is essentially non-fluorescent until it is nitrosylated by products of oxidation of NO, resulting in DAF-FM triazole which exhibits about a 160-fold greater fluorescence quantum efficiency at 495 nM. Un-labeled activated T-cells were cultured in presence and absence of naïve BM-derived sorted CD11b + cells. After 4 days cells were harvested from culture, washed with PBS, incubated with 10 mM DAF-FM for 45 min at 37uC, washed once with PBS and then incubated for additional 20 minutes to complete de-esterification of intracellular di-acetates.
Data analysis
Statistical analyses were performed using Graph Pad Prism Software (OS X version 5.00 for Macintosh, Graph Pad, San Diego, California, USA). Differences between groups were analyzed using unpaired two-tailed Student's t test and MannWhitney test. P,0.05 was considered statistically significant. Quantitative data are presented as mean 6 SD.
Results
BM of non-tumor-bearing mice contains CD11b
+ GR-1
+
IMCs with potent suppressive activity that limits T-cell activation and proliferation
To assess the potential of BM-derived CD11b + GR-1 + IMCs to limit T-cell activation and proliferation, we purified IMCs from BM of tumor-free mice that had a phenotype comparable to that of MDSC from tumor-bearing mice. Single cell suspensions of BM were prepared from naive C57BL/6 mice and stained with a cocktail of lineage markers, CD11b and GR-1. We used fluorescence-activated cell sorting (FACs) to isolate the following BM populations: all nucleated cells (gated by scatter parameter), lineage (+) cells, lineage (2) 1A) . To characterize the immunosuppressive properties of myelo-monocyte progenitors from non tumor-bearing mice, we isolated the GR-1 + granulocytic and GR-1 + monocytic subpopulations of IMCs by. We cultured the total population of lineage (2) 
FACS-purified lineage (2) BMCs and CD11b
+ GR-1 + IMCs had more suppressive activity than lineage (+) BMCs (Fig. 1D) . In order to evaluate the effect of IMCs on T-cell activation as well as T-cell division, we analyzed CD25 and Ki-67 expression on Tcells cultured alone and with CD11b
+ GR-1 + IMCs. Our data showed higher expression of CD25 on T-cells after activation with anti-CD3/CD28 Dynabeads compared with T-cells co-cultured with IMCs (Fig. S1A) . To understand the effect of IMCs on the viability of T-cells, cultures were stained with Trypan blue. We found a modest decrease in viable cells containing both T-cells and IMCs in contrast to expansion of viable cells in wells containing bead-activated T-cells alone (Fig. S1 B & S1 C). CFSE divided Tcells from control bead-activated cultures had more than 5-fold higher Ki-67 expression compared with CFSE divided T-cells that had been co-cultured with CD11b
+ GR-1 + IMC sorted cells, indicating that IMC suppress both T-cell activation and cell division (Fig. S2 ). Immunophenotype analysis of BM-derived CD11b
IMCs showed co-inhibitory markers (PDL-1& PDL-2), MHC class II, and co-stimulatory molecules CD80, CD86 were absent on both mononcytic and granulocytic IMC subpopulations (Fig. 1A) . Expression of CD49d was higher on the CD11b
int monocytic fraction, and expression of LFA-1 and CD62L were equivalent in both sub populations of CD11b + GR-1 hi myeloid cells. Similar to the published descriptions of MDSC subtypes isolated from spleens of tumor-bearing mice [17, 18] , both granulocytic (Ly6G + Ly6C dim ) and monocytic (Ly6G 2 Ly6C bright ) BM-derived IMCs expressed Ly-6C (Fig. 2) .
Suppressive capacity of naïve BM-derived CD11b
+
IMCs is comparable with MDSCs from tumor-bearing mice
A variety of studies have reported that MDSCs in tumorbearing animals have immune-suppressive effects on T-cell proliferation [9, 19, 20] . To compare suppressive activity of CD11b + GR-1 + IMCs isolated from the BM of non-tumor bearing mice with BM and spleen-derived MDSCs from tumor-bearing animals, we sorted myeloid progenitors from tumor-bearing and non-tumor-bearing mice and determined their suppressive activity by titrating ratios of myeloid cells: T-cells and measuring T-cell proliferation in vitro. We harvested BM and spleen from nontumor-bearing BALB/c mice and 4T1-tumor-bearing mice and sorted CD11b + GR-1 + myeloid progenitors. BM-derived IMCs from non-tumor bearing mice and MDSCs from tumor-bearing mice were co-cultured with CFSE-labeled splenocytes in the presence of anti CD3/CD28 Dynabeads, and T-cell proliferation analyzed by flow cytometry after 5 days of culture. The suppressive activity of BM-derived MDSCs from tumor-bearing mice and BM-derived IMCs from non-tumor bearing mice was similar based upon inspection of the CFSE staining histogram profiles of CD8 + T-cells (Fig. 3A) . Based upon the titration of myeloid cells: T-cells in culture, CD11b
+ GR-1 + IMCs from nontumor-bearing mice and CD11b
+ GR-1 + MDSCs from tumorbearing mice had nearly equivalent potency as assessed by the myeloid: T-cell ratio sufficient to achieve half-maximal suppression of T-cell proliferation (Fig. 3B ).
CD11b
+ IMCs induce T-cell apoptosis
Several studies have demonstrated that macrophages isolated from tumor-bearing mice may induce apoptosis of T-cells [21] [22] [23] . The ability of CD11b
+ IMCs from non-tumor-bearing B6 mice to induce T-cell apoptosis was assessed by measuring Annexin V and 7-AAD staining in Dynabead-stimulated T-cells cultured for 1, 2, 3 and 4 days with purified IMCs. The majority of T-cells (76%62.1 of CD8 + and 64%64.94 of CD4 + T-cells) had undergone apoptosis after 3 days co-culture with CD11b
+ GR-1 + IMCs compared to 48%65% of CD8 + and 29%62% of CD4 + Tcells cultured alone with anti CD3/CD28 beads (p,0.05) (Fig. 4A)(Fig. S1 D& E) . There was no correlation between Tcell division and expression of Fas, FasL, CD27 or 4IBBL on Tcells (data not shown), suggesting that T-cell apoptosis in cocultures with CD11b
+ GR-1 + IMCs did not result from activationinduced cell death. To test whether CD11b + GR-1 + IMCs had a general cytotoxic effect on lymphoid cells, we co-cultured a T-cell lymphoblastic lymphoma cell line LBRM with sorted IMCs and measured viability and proliferation of LBRM detected using Trypan Blue staining. IMCs did not inhibit proliferation or induce apoptosis of LBRM, indicating that the ability of IMCs to inhibit T-cell proliferation and induce apoptosis is not a generalized effect on dividing cells (Fig. 4B) .
Neutralizing antibody to IL-4 and IFN-c KO IMCs partially abrogate IMC-suppression
Several publications, using a variety of murine tumor models, have identified IL-4 and TGFb-dependent suppressive effects of tumor associated MDSCs [24, 25] . To assess the possible roles of these cytokines in the suppressive activity of IMCs in the bone marrow of non-tumor-bearing mice, we added neutralizing antibodies to IL-4, IL-10 and TGFb1 to cultures of mitogen activated T-cells co-cultured with CD11b
A partial restoration of T-cell proliferation was seen following the addition of anti-IL-4 antibody while neutralizing antibodies to TGFb1 and IL-10 did not restore T-cell proliferation (Fig. 5A) . Next we studied the roles for IDO, IFN-c and IL-12 in the suppressive activity of IMCs, since these molecules are also known to be involved in immunosuppressive signaling [26] [27] [28] . IMCs from IL-12 knockout mice (data not shown), and IDO knock out mice had inhibitory capacity similar to wild type IMCs, and T-cells from IFN-c KO mice did not show reduced proliferation in the presence of wild-type IMCs. In contrast, IMCs from IFN-c receptor KO mice were substantially less potent in inhibiting Tcell proliferation (Fig. 5B) . We did not detect significant expression of Foxp3 on CD4 + /CD25 + T-cells after 4-5 days co-culture with IMCs; suggesting IMC-mediated suppression is not through the induction or de novo generation of T-Regulatory cells (data not shown). 
IFN-c production by T-cells licenses NO production by CD11b
+ GR1 + IMCs
As nitric oxide (NO) is considered to be a key component in Tcell suppression mediated by MDSCs [29, 30] , we measured the role of NO in co-cultures of T-cells and IMCs to determine whether NO serves as a short-range soluble mediator that could inhibit T-cell proliferation. Extracellular NO was significantly higher in cultures of T-cells co-cultured with CD11b + GR1 + IMCs compared with media from cultures of Dynabead activated T-cells alone (Fig. 6A) . To confirm the effect of IMC on NO produced in co-cultures of T-cells and IMC, we measured extracellular NO concentration in media of co-cultures of T-cells with CD11b
+ IMCs in which the numbers of IMCs were progressively decreased (Fig. S4 ) and used flow cytometry to measure intracellular NO in IMCs and T-cells from co-cultures (Fig. S5) . Our results showed that co-culture of CD11b + GR-1 + with T-cells lead to enhanced NO production in the IMC population. Consistent with the previously described role for IFNc signaling in the immuno-suppressive activity of MDSCs, extracellular NO was significantly lower in supernatants of cocultures of wild-type T-cells and CD11b + GR1 + IMCs isolated from IFN-c receptor KO mice compared with supernatants of IFN-c KO T-cells cultured with wild type IMCs (Fig. 6B, filled  bars) . To better understand the relationship between IFN-c signaling, NO and suppression of T-cell proliferation, we measured NO production after adding IFN-c (50 ng/ml) to the same T-cell/IMC co-cultures described above (white bar graphs left to right). Our results show significantly less NO production by IFN-c receptor KO CD11b + GR1 + IMCs than wild type IMCs, demonstrating a role for IFN-c signaling receptors on IMCs in NO production. Adding iNOS inhibitors (L-NMMA, L-NIO, and L-NIL) to co-cultures of T-cells with IMCs restored T-cell proliferation (Fig. 6C) . Measurement of extracellular NO in the culture media from multiple experiments showed a high correlation between NO and the degree to which T-cell proliferation was inhibited (Fig. 6D ).
Viability and cell-to-cell contact are required for BMderived CD11b + GR1 + IMC mediated suppression
Given the close proximity of IMCs with T-cells in the bone marrow microenvironment, we next asked whether cell-cell contact between T-cells and IMC was required for suppressing T-cell proliferation. Physical separation of T-cells and IMCs in a Transwell culture nearly completely abrogated the suppressive activity of bone marrow IMCs. The percentage of divided T-cells after activation by Dynabeads increased by 5-fold compared with T-cells and IMCs co-cultured in the same culture chamber, indicating that direct T-cell-to cell contact or the production of short-range soluble mediators are required for the suppressive effect of IMCs (Fig. 7A) . We tested whether viability of IMCs was required for their observed suppressive activity by fixing IMCs with PFA. Fixation of IMCs significantly abrogated their suppressive activity on mitogen activated T-cells (Fig. 7B) . Taken together, these data indicate that suppression of T-cell proliferation requires contact with live IMCs, likely due to signaling through cell surface receptors or short-range soluble mediators.
Discussion
This work was undertaken to characterize the ability of myeloid precursors from the BM of non-tumor-bearing mice to inhibit Tcell proliferation. In contrast to previous studies that suggested BM-derived CD11b + GR-1 + IMCs from tumor-free mice lack immunosuppressive activity [8] , this is the first study to definitively document that CD11b
+ GR-1 + IMCs isolated from the BM of non tumor-bearing mice have comparable ability to suppress T-cell proliferation as MDSCs from tumor-bearing mice. While previous reports characterized the suppressive effect of CD11b
+ from cytokine-activated bone marrow and spleen [26, 31, 32] , and the immunosuppressive activity of CD11b + Ly6C + Ly6G 2 mononuclear cells in the blood of non-tumor-bearing mice [33] , and multiple hematopoietic tissues (BM, blood, spleen, and peripheral lymph nodes) of healthy aged mice [34] , we studied IMCs purified from non-stimulated bone marrow by FACS. It is likely that the administration of cytokines changes the immuno-modulatory properties of myeloid progenitors [35] , and that granulocytic cells isolated from the blood have different immuno-modulatory properties than immature myeloid cells in the bone marrow. Of note, the BM-derived CD11b + GR-1 + IMCs from non-tumorbearing mice expressed a different pattern of cell surface markers than splenocyte derived MDSCs from tumor-bearing mice (Fig.  S3) . Specifically, IMC lack expression of CD124 and PDL-1, two markers associated with immuno-suppression [18, 36, 37] . These results indicate that tumor-associated signals can lead to specific patterns of differentiation of myeloid progenitors, compared with IMCs isolated directly from bone marrow. Our findings indicate that the suppression activity of CD11b + GR-1 + IMCs is mediated in vitro (in part) through local production of NO that suppresses Tcell proliferation. Of note, apoptosis of T-cells co-cultured with IMCs was induced, while LBRM, a T-cell lymphoma cell line, cocultured with IMC did not undergo apoptosis. The different susceptibility of normal T-cells versus malignant T-cells to IMCinduced apoptosis may reflect intrinsic anti-apoptotic mechanisms activated in the malignant T-cell population. Previous studies showed T-cells could be a source of NO production [30] . Our findings showed that co-culture of immature myeloid cells with Tcells leads to enhanced NO production in the IMC population. significant correlation between NO and the inhibition of T-cell proliferation. Our findings with IMCs from normal BM are consistent with published work on MDSCs from tumor-bearing animals that have established the role for IFN-c in suppressing Tcell proliferation [26, 38] . In contrast to previous reports of a critical role for IDO or IL-12 pathways in the suppressive effect of MDSCs in tumor models [27, 39] , we did not identify the requirement for these pathways in the suppressive effect of IMCs from non-tumor-bearing mice on T-cell proliferation. However, blocking the activity of IL-4 partially restored T-cell proliferation, suggesting that IL-4 signaling may suppress T-cell proliferation independent of the iNOS/NO pathway. Of note, there may be a role for other soluble mediators like prostaglandin E2 (PGE2), that regulate T-cell proliferation as physiological mediator of cell survival and differentiation via receptors are present on murine and human hematopoietic stem and progenitor cells [40] and on MDSCs [41] . Further experiments need to clarify possible roles for mediators like PGE2 in the immuno-suppressive activity of IMCs.
Taken together, these findings suggest that BM-derived IMCs may have an important physiological role in creating and maintaining an immunosuppressive state for T-cells in the bone marrow microenvironment. Our findings are consistent with reports indicating qualitative differences in the alloreactivity of Tcells isolated from BM versus splenic T-cells and their contribution to an immunosuppressive microenvironment [42, 43] . Further experiments might help to elucidate the immunoregulatory mechanisms of IMCs in maintaining an immuno-suppressive state in the BM microenvironment in vivo. 
